Symbiotec Pharmalab IPO
Listed +0.0%24–27 Aug 2026
Share: WhatsApp ·
Our IPO analysis
What stands out in the offer document
The five questions
-
1How it makes money₹96 of every ₹100 of sales comes from its "Sale of APIs" segment.
-
2Is it growing, and is profit turning into cash?Sales rose 21% from 2024 to 2026 (₹716 cr → ₹869 cr). Over 3 years it made ₹307 cr of profit and brought in ₹409 cr of cash from operations.
-
3How much cushion does it have?It owes ₹0.34 for every ₹1 of its own money. The line for pharmaceuticals / api is ₹1.5.
-
4What you pay, and who gets the moneyOf every ₹100 raised, ₹91 goes to existing shareholders selling. At ₹988 you pay about ₹54 for every ₹1 of last year's profit.
-
5Who controls it, and what is on record?Promoters own 29% before the IPO.
From the draft document. The final prospectus may change it.
Never miss an IPO like this
One free email when each IPO opens: subscription, GMP and the DRHP breakdown.
Latest update:
Listed at ₹988 vs ₹988 issue price (+0.0%) · Day-one close ₹1,098 · GMP before listing +20.7% implied, 20.7 pp above the actual open · Subscribed 71.26× (QIB 172.0× · NII 73.6× · Retail 13.0×) · Price band ₹938–₹988 · Closed 27 Aug 2026 · Listed 1 Sep 2026 (Confirmed)
How it actually listed
₹988 on open, against a ₹988 issue price +0.0%
It ended its first day at ₹1,098 (+11.1% against the issue price), per the NSE's price archive.
On the BSE it opened at ₹978 and closed at ₹1,096, per the BSE's price archive.
Before it listed, the grey market implied +20.7%. The shares opened 20.7 pp below what that implied. It pointed the wrong way on whether they would open above the issue price. GMP is unregulated and self-reported.
What Symbiotec Pharmalab does
Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology, and complex injectables. The company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) in volume terms.
Symbiotec Pharmalab financials
Rs crore · Annual| 2024 | 2025 | 2026 | ||
|---|---|---|---|---|
| Sales | 716 | 752 | 869 | |
| Operating Profit | 177 | 206 | 232 | |
| OPM % | 24.5% | 27.3% | 26.6% | |
| Net Profit | 100 | 97 | 110 | |
| Total Debt | 251 | 544 | 391 |
Symbiotec Pharmalab IPO offer structure
Total: ₹1,757 cr. Fresh issue proceeds go to the company; OFS proceeds go to selling shareholders.
Size and split come from a public aggregator rather than the exchange, cross-checked against a second.
Use of proceeds- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company: ₹113 cr
- General corporate purposes
Symbiotec Pharmalab promoters and holding
- Anil Satwani: Promoter, Chairman and Managing Director
- Kashish Satwani: Promoter
- Sushil Satwani: Promoter
- Satwani Holdings LLP: Corporate Promoter
Symbiotec Pharmalab risks and strengths
- We derive almost all of our revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. (p.28)
- Our manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and our customers. (p.30)
- We export our products to various countries and our revenue from external customers outside India represented 67.04%, 55.19% and 59.97% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. (p.31)
Symbiotec Pharmalab market and competition
We have a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients ('APIs') in volume terms in Fiscal 2026, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs. We held a market share of over 50% by volume in products such as Hydrocortisone, Testosterone and Methylprednisolone in Fiscal 2026.
Symbiotec Pharmalab IPO: common questions
When does the Symbiotec Pharmalab IPO open and close?
The Symbiotec Pharmalab IPO is open from 24 Aug 2026 to 27 Aug 2026.
What is the Symbiotec Pharmalab IPO price band?
The price band is ₹938–₹988 per share.
What is the lot size and minimum investment for the Symbiotec Pharmalab IPO?
One lot is 15 shares, and a retail application must be at least one lot. That is about ₹14,820 at the upper end of the band. An HNI application starts above Rs 2 lakh, so the minimum is higher for that category.
How much is the Symbiotec Pharmalab IPO subscribed?
As of 10 Oct 2026 the total subscription is 71.26×.
When does the Symbiotec Pharmalab IPO list?
The listing date is 1 Sep 2026.
How do I check the Symbiotec Pharmalab IPO allotment status?
On the allotment status page published by MUFG Intime India, this issue's registrar, and on the exchange's basis of allotment. Those are the primary sources. If the issue was oversubscribed, retail allotment was decided by lottery, so a valid application does not mean shares. We do not hold allotment data and cannot look yours up. How allotment is actually decided →
Symbiotec Pharmalab IPO allotment status
Listed 1 Sep 2026. Allotment is decided and published by the registrar, not by us. This issue's registrar is MUFG Intime India.
Check your allotment on the registrar's own page ↗
We do not hold allotment data and cannot look yours up. If the issue was oversubscribed, retail allotment was decided by lottery, so a valid application does not mean shares. How allotment is actually decided →